Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lercanidipine suffers another setback

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Forest says further development of the calcium channel blocker lercanidipine would require another extended-release formulation, after the current modified-release version failed to meet dose-response criteria in a Phase II study conducted in response to FDA's August 2002 "approvable" letter. Preliminary results of the eight-week, 60-patient efficacy study indicate lercanidipine was "well tolerated" and had a "clinically relevant reduction in blood pressure." Forest says the positive findings warrant further investigation. A new formulation would mean development "would accordingly be somewhat delayed," the company says. Lercanidipine is already three years behind the original launch projection…
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel